Patients with dry eye disease experienced improvements in ocular discomfort after treatment with reproxalap, according to a press release from Aldeyra Therapeutics.
“We are pleased with the results as the primary endpoint was definitively achieved with a P value of .004,” Todd C. Brady, MD, PhD, president and CEO of Aldeyra, told Healio.
In a phase 3 randomized, double-masked, vehicle-controlled clinical trial investigating 0.25% reproxalap ophthalmic solution, 66 patients received reproxalap and 66 patients received vehicle before and during exposure to a dry eye chamber.
The study